<DOC>
	<DOC>NCT00559455</DOC>
	<brief_summary>Primary objective: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV Secondary objective: To evaluate time to progression, 6month survival, overall survival, safety and tolerability of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV</brief_summary>
	<brief_title>Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Lists of Inclusion and Exclusion criteria: Patients must have histologically confirmed hepatocellular carcinoma Patients must have measurable disease by CT scan Have not received previous palliative systemic chemotherapy for metastatic disease. (Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.) Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, TransArtery Embolization or TransArtery ChemoEmbolization) or at least 4 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion. WHO 02 grades (Karnofsky Performance Score ≥ 70) Patients must have adequate organ and marrow function: Neutrophilus ≥ 1.5 x 10^9/L Platelets ≥ 75 x 10^9/L Asparagine AminoTransferase, Alanine AminoTransferase &lt; 2.5 x Upper Normal Limit(UNL) Total Bilirubin ≤ 1.5 x UNL International Normalized Ratio &lt; 1.5 Child stage A or B Creatinine ≤ 1.5 X UNL Documented allergy to platinum compound or to other study drugs. Active GastroIntestinal bleeding and active haematologic malignancy Previous liver transplantation. Patients concomitantly receiving any other anticancer therapy. Patients who are receiving any other study treatments. Pregnant or lactating women or women of childbearing potential without proper contraceptive methods. History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma insitu of uterine cervix. Central nervous system metastasis Other serious illness or medical conditions Neuropathy ≥ grade 2 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>